Latest Medical Devices News

Cyclopharm has launched a pioneering clinical study combining its Technegas imaging with AI analysis to explore a novel treatment for severe COPD, potentially expanding care options for millions.

Vitrafy Life Sciences has marked significant progress in Q2 FY2026 with a strategic partnership, commercial launch in North America, and advancing clinical trials, underpinning its growth in cryopreservation technology.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Epiminder Limited has successfully listed on the ASX, raising $125 million to commercialise its FDA-approved Minder device. The company has initiated the first US implant and secured five leading medical centres for its DETECT study.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Following its December 2025 ASX debut and a successful IPO, Saluda Medical reports robust global revenue growth and expands its US sales force, prompting an upward revision of its FY26 revenue guidance.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

EMVision Medical Devices reports strong progress in its emu™ Brain Scanner clinical trials, expanding recruitment across seven leading stroke hospitals and introducing new software features to enhance scan quality.

Control Bionics has partnered with Tobii Dynavox to pilot its NeuroNode technology across five US states, aiming to enhance communication access for users of augmentative devices.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.